2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.
Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in...
2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants...
2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and...
2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.35 | -8.83838383838 | 3.96 | 3.96 | 3.02 | 358874 | 3.3000407 | CS |
4 | -1.33 | -26.9230769231 | 4.94 | 5.12 | 3.02 | 343226 | 4.32368328 | CS |
12 | -1.24 | -25.5670103093 | 4.85 | 5.3 | 3.02 | 308856 | 4.60658579 | CS |
26 | -0.78 | -17.7676537585 | 4.39 | 5.3 | 3.02 | 394544 | 4.39457292 | CS |
52 | 1.99 | 122.839506173 | 1.62 | 6.4 | 1.535 | 898356 | 4.21561563 | CS |
156 | -32.53 | -90.0110680686 | 36.14 | 36.15 | 1.535 | 808720 | 7.96132098 | CS |
260 | -22.52 | -86.1844623039 | 26.13 | 44.34 | 1.535 | 805581 | 8.26720716 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관